1
|
Yi H, Ou-Yang X, Hong Q, Liu L, Liu M, Wang Y, Zhang G, Ma F, Mu J, Mao Y. Patient-reported outcomes in lung cancer surgery: A narrative review. Asian J Surg 2024:S1015-9584(24)01677-4. [PMID: 39117541 DOI: 10.1016/j.asjsur.2024.07.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2024] [Revised: 07/17/2024] [Accepted: 07/25/2024] [Indexed: 08/10/2024] Open
Abstract
Lung cancer is a leading cause of cancer-related mortality worldwide, profoundly affecting patients' quality of life. Patient-reported outcomes (PROs) provide essential insights from the patients' perspective, a crucial aspect often overlooked by traditional clinical outcomes. This review synthesizes research on the role of PROs in lung cancer surgery to enhance patient care and outcomes. We conducted a comprehensive literature search across PubMed, Scopus, and Web of Science up to March 2024, using terms such as "lung cancer," "Patient Reported Outcome," "lobectomy," "segmentectomy," and "lung surgery." The criteria included original studies on lung cancer patients who underwent surgical treatment and reported on PROs. After screening and removing duplicates, reviews, non-English articles, and irrelevant studies, 36 research articles were selected, supported by an additional 53 publications, totaling 89 references. The findings highlight the utility of PROs in assessing post-surgical outcomes, informing clinical decisions, and facilitating patient-centered care. However, challenges in standardization, patient burden, and integration into clinical workflows remain, underscoring the need for further research and methodological refinement. PROs are indispensable for understanding the quality-of-life post-surgery and enhancing communication and decision-making in clinical practice. Their integration into routine care is vital for a holistic approach to lung cancer treatment, promising significant improvements in patient outcomes and quality of care.
Collapse
Affiliation(s)
- Hang Yi
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Xu Ou-Yang
- Shantou University Medical College, Shantou, 515041, China
| | - Qian Hong
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Lu Liu
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Man Liu
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Yan Wang
- The Johns Hopkins University, Bloomberg School of Public Health, Epidemiology, Baltimore, MD, USA
| | - Guochao Zhang
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Fengyan Ma
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
| | - Juwei Mu
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
| | - Yousheng Mao
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
| |
Collapse
|
2
|
Lu S, Chi Z, Wang J. Influence of humanistic care on nursing quality and patient psychology of advanced non-small cell lung cancer. Panminerva Med 2023; 65:437-439. [PMID: 35913100 DOI: 10.23736/s0031-0808.22.04749-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/27/2023]
Affiliation(s)
- Shaoping Lu
- Positive Hemodialysis Room, Yantai Hospital of Traditional Chinese Medicine, Yantai, China
| | - Zhaorui Chi
- Department of Obstetrics and Gynecology, Yantai Hospital of Traditional Chinese Medicine, Yantai, China
| | - Jihua Wang
- Department of Oncology, Yantai Hospital of Traditional Chinese Medicine, Yantai, China -
| |
Collapse
|
3
|
Monteiro MR, Nunes NCC, Crespo J, Abrahão ABK, Buscacio G, Lerner LCC, Sermoud L, Arakelian R, Piotto G, Lemos C, Campos R, Victorino D, Andrade PM, Ferreira TAV, Pecoraro JP, Meton F, Gaui MF, Araujo LH. Patient-centered Outcomes in Breast Cancer: Description of EQ-5D-5L and EORTC-QLQ-BR23 Measurements in Real-world Data and Their Association With Survival. Clin Oncol (R Coll Radiol) 2022; 34:608-616. [PMID: 35667940 DOI: 10.1016/j.clon.2022.05.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Revised: 04/25/2022] [Accepted: 05/18/2022] [Indexed: 11/27/2022]
Abstract
AIMS In recent years, major improvements in breast cancer treatments have led to a significant increase in survival. Despite that, this population's quality of life (QoL) information is lacking, especially real-world data. MATERIALS AND METHODS This was a prospective, multicentre, observational study of female breast cancer patients, without prior systemic treatment, treated between 2012 and 2019 in private health care in Brazil. QoL was assessed by two questionnaires, the EQ-5D-5L and the EORTC-QLQ-BR23. Additional data were retrospectively collected. RESULTS The study comprised 1372 patients, most with early-stage disease (80.2% stages 0-II). At a median follow-up of 25.6 months, the estimated 3-year overall survival was 93.6%. Patients with locally advanced and metastatic breast cancer had the lowest visual analogue scale scores and the highest symptom burden in all dimensions of EQ-5D-5L, but with the most significant improvement after treatment. With the EORTC-QLQ-BR23 questionnaire, patients undergoing lumpectomy had a better perception of body image. Axillary dissection led to greater arm symptoms after 12 months, radiotherapy enhanced breast symptoms and patients treated with chemotherapy had significant worsening in the effects of systemic therapy compared with endocrine or HER2 therapy. Staging and immunohistochemical subtype correlated with survival and with several QoL parameters, but overall survival was not independently affected by patient-reported outcomes in this cohort. CONCLUSION Our results show that early diagnosis and access to treatments with fewer side-effects, such as endocrine or targeted therapy, and less aggressive surgeries are the best strategies to achieve a better QoL for breast cancer patients.
Collapse
Affiliation(s)
- M R Monteiro
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil.
| | - N C C Nunes
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - J Crespo
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - A B K Abrahão
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - G Buscacio
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - L C C Lerner
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - L Sermoud
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - R Arakelian
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - G Piotto
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - C Lemos
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - R Campos
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - D Victorino
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - P M Andrade
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - T A V Ferreira
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - J P Pecoraro
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - F Meton
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - M F Gaui
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| | - L H Araujo
- COI Institute, Clinical Research Department, Americas Oncology Cancer Center, São Paulo, Brazil
| |
Collapse
|